Fumarate-enriched blood cardioplegia results in complete functional recovery of immature myocardium.
Amino acid enrichment of cardioplegic solutions has been shown to improve both the metabolic and functional recovery of ischemic myocardium. However, because of the marked systemic vasodilatation involved, use of amino acid enrichment is limited to the periods of induction and reperfusion. Fumarate is a Krebs' cycle intermediate whose conversion to succinate is responsible for the generation of adenosone triphosphate and the oxidation of the reduced form of nicotinamide-adenine nucleotide which is the pathway by which aspartate exerts its effect. Fumarate may also function as a free-radical scavenger and is involved in calcium transport. To determine if fumarate-enriched blood cardioplegia would improve the functional recovery of the neonatal heart, 14 neonatal piglet hearts were isolated and placed on a blood-perfused working heart circuit. After the baseline functional and metabolic assessment was done, cold ischemic arrest was initiated with either standard blood cardioplegic solution (group I; N = 7) or fumarate-enriched (13 mmol/L) blood cardioplegic solution (group II; N = 7). Cardioplegic solution was given at a pressure of 40 mm Hg every 20 minutes for 2 hours, and topical hypothermia was used. Sixty minutes after warm whole blood reperfusion, the functional recovery at left atrial pressures of 3, 6, 9, and 12 mm Hg was 70%, 66%, 66%, and 65%, respectively, in group I, versus 102%, 106%, 105%, and 109%, respectively, in group II (p < 0.05). The tissue creatinine phosphate levels after reperfusion were significantly higher in group II hearts (15.0 +/- 1.2 mumol/g dry heart tissue) than in group I hearts (9.2 +/- 1.9 mumol/g dry heart tissue), although the adenosine triphosphate levels were not significantly different.(ABSTRACT TRUNCATED AT 250 WORDS)
Pearl
J M
JM
Department of Surgery, University of California at Los Angeles Medical Center 90024.
Hiramoto
J
J
Laks
H
H
Drinkwater
D C
DC
Chang
P A
PA
D000255:Adenosine Triphosphate / Q000032:analysis; D000818:Animals; D000831:Animals, Newborn; D016275:Atrial Function / Q000502:physiology; D001769:Blood; D001794:Blood Pressure / Q000502:physiology; D002302:Cardiac Output / Q000502:physiology; D002314:Cardioplegic Solutions / Q000627:therapeutic use*; D005650:Fumarates / Q000627:therapeutic use*; D006321:Heart / Q000502:physiology*; D006324:Heart Arrest, Induced; D007036:Hypothermia, Induced; D007773:Lactates / Q000032:analysis; D015425:Myocardial Reperfusion; D009206:Myocardium / Q000737:chemistry / Q000378:metabolism*; D010725:Phosphocreatine / Q000031:analogs & derivatives / Q000032:analysis; D013318:Stroke Volume / Q000502:physiology; D013552:Swine; D013997:Time Factors; D016277:Ventricular Function, Left / Q000502:physiology
D002314:Cardioplegic Solutions; D005650:Fumarates; D007773:Lactates; D010725:Phosphocreatine; C025403:phosphocreatinine; C032005:fumaric acid; D000255:Adenosine Triphosphate